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Abstract: Bisphosphonates are the leading drugs for the treatment of osteoporosis. In 
  randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to 
reduce the risk of vertebral, nonvertebral, and hip fractures, whereas RCTs with ibandronate 
show antifracture efficacy at vertebral sites. Bisphosphonates are generally well tolerated and 
safe. Nevertheless, adverse events have been noted, and it is important to consider the strength 
of the evidence for causal relationships. Effects on the gastrointestinal tract and kidney function 
are well recognized, as are transient acute-phase reactions. Atrial fibrillation was first identified 
as a potential adverse event in a zoledronate trial, but subsequent trials and analyses failed to 
substantiate an association with bisphosphonates. Case reports have suggested a relationship 
between oral bisphosphonates and esophageal cancer, but this has not been demonstrated in 
epidemiologic studies. A possible association between bisphosphonate use and osteonecrosis of 
the jaw (ONJ) has also been suggested. However, the risk of ONJ in patients with osteoporosis 
appears to be very low, with no evidence from prospective RCTs of a causal association. There 
are reports of occasional occurrence of subtrochanteric or diaphyseal fractures in osteoporotic 
patients, but an association with bisphosphonate therapy is not substantiated by epidemiologic 
studies or prospective RCTs.
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Introduction
Osteoporosis is a common disease characterized by low bone mass and structural dete-
rioration of bone tissue, resulting in decreased bone strength and increased susceptibility 
to fractures.1 At menopause, estrogen production declines, leading to unbalanced bone 
remodeling. Bone resorption occurs at a higher rate than bone formation and, as a result, 
bone is progressively lost, leading to postmenopausal osteoporosis and an increased risk 
of fragility fractures.2 Vertebral fractures can lead to chronic pain and deformity with 
advanced disease. Both hip and spine fractures are associated with increased mortality, 
and a substantial economic burden.3–5 Therapeutic interventions that mitigate fracture risk 
are, therefore, essential for reducing the consequences of this debilitating condition.
Nitrogen-containing bisphosphonates, such as alendronate, risedronate, iban-
dronate, and zoledronate (also known as zoledronic acida), are agents that inhibit 
bone resorption, and are currently used as first-line treatment for osteoporosis.6,7 Their 
aAll bisphosphonates exist as salts rather than acids at physiological pH, so it is not technically accurate for 
zoledronate to be called zoledronic acid. To be consistent with the nomenclature for other bisphosphonates, 





antiresorptive action results from both their affinity for bone 
mineral and their inhibitory effect on osteoclast cell function. 
Significant differences in binding affinity to bone mineral 
have been found among the bisphosphonates in vitro, with 
a rank order of highest to lowest as follows: zoledronate 
. alendronate . ibandronate . risedronate.8,9 Similarly, 
the degree to which bisphosphonates reduce osteoclastic 
activity by inhibition of farnesyl pyrophosphate synthase 
also differs among them, with a rank of order from highest 
to lowest as follows: zoledronate . risedronate . iban-
dronate . alendronate.10,11 These differences are explained 
principally by the three-dimensional configuration of each 
bisphosphonate and, as a result, each bisphosphonate offers 
a unique combination of pharmacologic properties.7 As a 
class, bisphosphonates increase the bone mineral density 
(BMD), decrease the levels of biomarkers of bone resorp-
tion, and reduce the risk of osteoporotic fractures. In 2004, 
55 million prescriptions for bisphosphonates were written in 
the United States alone.12 Clinically, the bisphosphonates are 
considered to be a very safe drug class, given their specific 
bone-targeting capability. However, there are some safety 
concerns that are discussed in this article.
This article reviews the key clinical profiles of the 
bisphosphonates commonly used for the treatment of post-
menopausal osteoporosis in terms of their efficacy in the 
reduction of fracture risk at vertebral and nonvertebral sites. 
It also reviews their safety profiles, including effects on the 
gastrointestinal tract (GI), musculoskeletal tolerability, renal 
safety, atrial fibrillation (AF), osteonecrosis of the jaw (ONJ), 
subtrochanteric or diaphyseal fractures, and possible adverse 
effects on bone turnover. In preparing this review, we have 
made a comprehensive search using PubMed with subject 
headings for the individual bisphosphonates. This covers the 
period up to December 2009. There have been other recent 
reviews covering some of these topics.13,14
Efficacy
Efficacy over the first 3 years  
of treatment
Four nitrogen-containing bisphosphonates have been 
approved in both the United States and in Europe: alen-
dronate, risedronate, ibandronate, and zoledronate. All these 
four bisphosphonates have met US Food and Drug Adminis-
tration (FDA) and European requirements for the treatment of 
osteoporosis by significantly decreasing morphometric ver-
tebral fractures over a 3-year treatment period. The approved 
nondaily oral regimens of weekly alendronate, weekly and 
monthly risedronate, and monthly ibandronate have not been 
evaluated in fracture-end point trials. Instead, it has been 
shown in bridging trials, based on BMD and bone biomark-
ers, that higher doses of these bisphosphonates coupled with 
longer intervals between doses result in equivalent results 
compared with their respective daily regimens.
Other bisphosphonates also have been used in osteoporosis 
but have not achieved broad indications and license. These 
include clodronate, pamidronate, tiludronate, neridronate, 
minodronate, and olpadronate. Etidronate was approved in 
most countries in the early 1990s. Pamidronate has been 
extensively used off-label for osteoporosis as it was the only 
intravenous (IV) bisphosphonate available. A further discus-
sion of these compounds is beyond the scope of this review.
In prospective double-blind randomized placebo-
controlled trials (RCTs), alendronate, risedronate, and 
zoledronate have been shown to reduce the risk of both 
vertebral and nonvertebral fractures, including those of the 
hip.15–21 Prospective studies with ibandronate have also shown 
antifracture efficacy at vertebral sites but did not show a sig-
nificant reduction in nonvertebral or hip fracture risk in the 
overall study population of the phase III fracture trial.22
Alendronate
Alendronate was the first oral nitrogen-containing bisphos-
phonate to be licensed for osteoporosis, initially in the United 
States, in 1995. The Alendronate Phase III Osteoporosis 
Treatment Study23 demonstrated a 48% overall reduction 
(P = 0.03) in the risk of radiographically defined vertebral 
fractures in women with low BMD. In the Fracture Inter-
vention Trial (FIT) that followed, 3 years of alendronate 
treatment (5 mg/day for 2 years followed by 10 mg/day for 
the last year) in women with previous vertebral fractures 
was shown to reduce the risk of vertebral and hip fractures 
by 47% (P , 0.001) and 51% (P = 0.047), respectively.15 In 
women with osteoporosis but no vertebral fracture, 4 years 
of alendronate treatment (5 mg/day for 2 years followed by 
10 mg/day for the remainder of the trial) was associated 
with a 44% (P = 0.002) reduction in the risk of vertebral 
fracture.16 Post hoc analyses of the pooled populations showed 
that alendronate treatment significantly reduced the risk of 
clinical vertebral fracture after 12 months of treatment (59%; 
P , 0.001), whereas hip and nonvertebral fracture risk were 
significantly reduced by month 18 and 24 (63%; P = 0.014 
and 26%; P = 0.011, respectively).24 The placebo-controlled 
Fosamax International Trial demonstrated that 1 year of 
treatment with alendronate (10 mg/day) reduced the risk 
of nonvertebral fractures by 47% (P = 0.021) in postmeno-
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twice-weekly (35 mg) and weekly (70 mg) dosing regimens 
of alendronate showed comparable efficacy to 10 mg daily 
dosing, based on changes from baseline in lumbar spine 
BMD.25,26
Risedronate
In the North American arm of the Vertebral Efficacy with 
Risedronate Therapy (VERT) trial, 3 years of treatment with 
risedronate (5 mg/day) in women with at least one vertebral 
fracture reduced the risk of a new vertebral fracture by 41% 
(P = 0.003), and was also associated with a 39% reduction 
in the risk of nonvertebral fracture (P = 0.02).18 In the mul-
tinational arm of the VERT trial, treatment with risedronate 
(5 mg/day) over 3 years significantly decreased the risk of 
new vertebral fractures by 49% (P , 0.001) in women start-
ing with at least two prevalent vertebral fractures. The risk of 
nonvertebral fractures was reduced by 33%, a nonsignificant 
difference compared with placebo (P = 0.06).19 In elderly 
women (70–79 years of age) with osteoporosis (T-score –4 or 
less, or T-score –3 or less and a nonskeletal risk factor for hip 
fracture), 3 years of treatment with risedronate was found to 
reduce the incidence of hip fracture by 40% compared with pla-
cebo (P = 0.009).20 Post hoc analyses from placebo-controlled 
trials enrolling postmenopausal women with osteoporosis 
(determined on the basis of prevalent vertebral fractures, low 
BMD, or both) have indicated that risedronate (5 mg/day) sig-
nificantly reduces the clinical vertebral and nonvertebral (66%; 
P = 0.048) fracture incidence as early as 6 months after begin-
ning treatment.27,28 In active-control studies, weekly (35 mg) 
and monthly (75 mg on two consecutive days per month 
[2CDM] or 150 mg once a month [OaM]) dosing regimens 
were found to be noninferior to daily (5 mg) dosing, based on 
mean increases from baseline in lumbar spine BMD.29–31 The 
studies with risedronate 75 mg 2CDM and 150 mg OaM also 
included new incident vertebral fractures as a second efficacy 
measure at 12 months. New vertebral fractures occurred infre-
quently and, in each of the two studies, the incidence of new 
vertebral fractures was similar between the monthly and the 
daily treatment groups.30,31 When examining different dosing 
regimens, some studies have compared the results of matched 
historical control data from previous placebo-controlled trials, 
as an alternative option when placebo controls are not practical 
or ethical. Thus, active-control studies with risedronate dosed 
at 35 mg weekly,32 75 mg 2CDM,33 or 150 mg OaM34 showed 
similar efficacy, as measured by BMD, to risedronate 5 mg 
daily over a period of 1 year, as well as a reduction in vertebral 
fracture risk of 77, 79, and 72%, respectively, compared with 
a historical placebo-control group.
ibandronate
The oral iBandronate Osteoporosis vertebral fracture trial 
in North America and Europe (BONE) demonstrated that 
3 years of oral treatment with ibandronate (2.5 mg/day) 
reduced the risk of vertebral fractures by 62% (P = 0.0001) 
in postmenopausal women with a BMD T-score –2.0 or 
less and 1–4 prevalent vertebral fractures.22 Although the 
evaluation of the overall population did not indicate a sig-
nificant reduction in the incidence of nonvertebral fractures, 
including those of the hip, a post hoc analysis of a higher-
risk subgroup (femoral neck BMD T-score –3.0 or less) 
showed a reduction of 69% in nonvertebral fracture risk 
(P = 0.012), but the significance of this has been questioned 
since the group with a T-score >−3.0 showed an increase 
in fracture incidence.7,22 The Monthly Oral Bandronate in 
Ladies (MOBILE) noninferiority trial compared the efficacy 
of monthly oral ibandronate regimens (50 mg 2CDM; or 
100 mg or 150 mg OaM) with daily dosing (2.5 mg) with 
ibandronate.35,36 The results indicated that all once-monthly 
regimens were at least as effective as daily treatment, whereas 
the 150 mg OaM regimen was found to be superior to the 
daily dosing, based on increases from baseline in lumbar 
spine BMD. Ibandronate can also be administered as an IV 
injection with extended dose-free intervals. To identify the 
optimal IV dosing regimen for postmenopausal women with 
osteoporosis, the Dosing IntraVenous Administration (DIVA) 
study compared the efficacy of 2-monthly (2 mg) ibandronate 
injection or 3-monthly (3 mg) ibandronate injection with 
the previously evaluated daily 2.5 mg oral formulation.37,38 
Based on mean increases in lumbar spine BMD, the results 
indicated that both IV regimens not only were noninferior 
but also produced larger increases than the oral daily dos-
ing. In a further analysis of the data collated from different 
studies on ibandronate, using estimates of annual cumulative 
exposure, it has been suggested that there might be effects 
on nonvertebral fractures at higher doses.39,40
Zoledronate
Zoledronate is the only bisphosphonate developed solely for 
use as an IV formulation, and is now routinely prescribed 
when IV therapy is indicated. The Health Outcomes and 
Reduced Incidence with Zoledronic acid ONce yearly 
(HORIZON) Pivotal Fracture Trial demonstrated the efficacy 
of a single yearly infusion of 5-mg zoledronate in postmeno-
pausal women with a BMD T-score –2.5 or less, or a BMD 
T-score –1.5 or less and prevalent vertebral fracture(s).21 Over 
a 3-year treatment period, the risk of vertebral, nonvertebral, 





(P , 0.01), and 41% (P = 0.002), respectively. Reductions 
in vertebral fracture risk were observed as early as 12 months 
after   initiation of treatment (60%; P , 0.001). Reductions 
in hip and nonvertebral fracture risk were observed at 
24 months. The HORIZON Recurrent Fracture Trial assessed 
the antifracture efficacy of zoledronate in patients (women 
and men) with a recent hip fracture.41 In this population, the 
rates of clinical vertebral and nonvertebral fracture were 
reduced by 46% (P = 0.02) and 27% (P = 0.03), respec-
tively, after 2 years of treatment. Notably, a reduction of 
28% (P = 0.01) in deaths from any cause was observed in 
the treatment group compared with placebo patients.42 This 
is an intriguing finding that merits further study, especially 
since other treatments for osteoporosis may also favorably 
affect mortality.43
Head-to-head trials
There are unfortunately very few direct comparisons of efficacy 
between bisphosphonates in clinical trials, and those available 
used surrogate end points such as BMD and markers of bone 
turnover rather than fractures. The Fosamax-Actonel Compari-
son Trial (FACT) was a 2-year head-to-head study comparing 
clinical outcomes between once-weekly alendronate 70 mg and 
once-weekly risedronate 35 mg. The results revealed greater 
gains in BMD and greater reductions in markers of bone turnover 
with alendronate compared with risedronate.44,45 In the nonin-
feriority head-to-head 1-year MOTION study, once-monthly 
ibandronate 150 mg was found to be clinically comparable 
to once-weekly alendronate 70 mg with regard to increasing 
BMD and decreasing bone turnover markers from baseline.46,47 
Nevertheless, it should be noted that although an increase in 
BMD can reflect lower fracture risk, larger increases in BMD 
do not necessarily result in greater reductions in vertebral or 
nonvertebral fracture risk.48 In fact, several studies have shown 
that increases in BMD are not directly proportional to decreases 
in fracture risk.48,49 Similarly, a reduction of bone resorption and 
turnover markers below a certain threshold may not lead to a 
further reduction of vertebral or nonvertebral fracture risk.50
Long-term efficacy (more than 3 years  
of treatment)
The clinical outcomes of treatment with alendronate, rise-
dronate, or zoledronate have been evaluated in the postmeno-
pausal setting for up to 10, 7, and 5 years, respectively.51–55 
The outcomes of administering ibandronate formulations in 
postmenopausal osteoporosis have so far only been reported 
for up to 3 years of treatment.
Alendronate
To evaluate the long-term efficacy of alendronate, a fol-
low-up long-term extension to the FIT trial was conducted. 
Patients assigned to alendronate therapy in the FIT trial 
were rerandomized for an additional 5 years to alendronate 
or placebo.51,52 Patients who were switched to placebo after 
5 years of treatment with alendronate (5 or 10 mg daily) had 
no increase in the risk of morphometric vertebral fractures 
or nonvertebral fractures over the next 5 years compared 
with patients who continued alendronate for up to 10 years. 
However, the risk of clinically diagnosed vertebral fractures 
was significantly lower (55%) among those who continued 
therapy compared with those who discontinued alendronate 
after 5 years of treatment.52 In summary, Black et al concludes 
that continuous treatment with alendronate beyond 5 years 
and up to 10 years may not be necessary for all patients, 
since discontinuing alendronate after 5 years does not appear 
to significantly increase fracture risk. Women at high risk of 
fractures may, however, benefit by continuing therapy with 
alendronate beyond 5 years of treatment.
Risedronate
To evaluate the long-term antifracture efficacy of rise-
dronate, the 3-year VERT multinational study was 
extended for an additional 2 years, during which patients 
continued double-blind treatment according to the original 
randomization. It was shown that the effects of risedronate 
on vertebral fracture risk over 3 years are maintained at 
the same magnitude with a further 2 years of treatment.53 
During years 4–5, vertebral fracture incidence was 59% 
lower with risedronate (5 mg/day) than with placebo 
(P = 0.01), whereas a 49% reduction in vertebral fracture 
risk had been seen in the first 3 years of treatment. At the 
end of the 5-year study period, all patients were offered 
open-label risedronate therapy (5 mg/day) for 2 additional 
years. In patients continuously treated with risedronate, the 
incidence of vertebral fractures during years 6–7 (3.8% 
per year) was similar to what was observed in years 4–5 
(5.2% per year) and years 0–3 (4.7% per year). The inci-
dence of nonvertebral fractures in years 6–7 was low and 
comparable to the incidence observed in the first 3 years.54 
In summary, results indicated that patients treated for up 
to 7 years with risedronate do not experience a decrease 
in the degree of fracture protection.
In the North American arm of the VERT study, patients 
stopped therapy as per protocol after 3 years and were given 
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which active treatment and placebo were discontinued. In the 
year off treatment, the BMD of patients previously treated 
with risedronate decreased but remained higher than base-
line BMD and the BMD of patients previously on placebo. 
The incidence of new vertebral fractures in the year after 
discontinuation of 3 years of treatment was 46% lower in the 
former risedronate group than in the former placebo group.56 
This antifracture effect and increase in biomarkers may still 
be seen after stopping treatment after 7 years.57
Zoledronate
The antifracture efficacy of zoledronate in the osteoporosis 
setting has not yet been reported beyond 3 years of treat-
ment for the 5 mg once-yearly dosing regimen.21 However, 
a smaller group of patients receiving a cumulative dose of 
2 mg annually and a larger group receiving a 4-mg dose were 
evaluated in a 5-year study. The study included an initial 
1-year, randomized, double-blind, placebo-controlled trial 
that was followed by 2 consecutive, open-label, 2-year exten-
sion studies. Treatment with zoledronate was associated with 
a sustained increase in BMD and reductions in bone turnover. 
The BMD gains achieved by month 36 were well maintained 
for a further 2 years in all patients.55 A bone turnover marker 
analysis during 2 years off treatment after 1 year of therapy 
has recently been reported and suggests that reduction of 
markers is comparable at 12 and 24 months.58
Tolerability and safety
To assess the tolerability and safety, it is important to take 
into account the way in which data are derived. Tolerability 
is best evaluated using prospective double-blind RCTs. Data 
regarding tolerability are derived in several ways from such 
studies, including recording the number of patients who 
withdraw from further participation, the reasons for these 
withdrawals such as adverse events, as well as the rate of 
discontinuation of study medication. It is also important to 
take into account the inclusion criteria used in the studies, 
as these may influence the reported rates of tolerability and 
adverse events. For example, the exclusion of patients with 
preexisting GI problems is likely to affect the rate at which 
GI events are recorded.
General safety
Bisphosphonates are one of the most thoroughly studied 
groups of drugs used in medicine. Since their first use in 
1969, their efficacy and safety have been established through 
a series of comprehensive trials for their various clinical 
uses, in Paget’s disease, in myeloma and bone metastases, 
as well as in osteoporosis. This includes the trials with 
nitrogen-containing bisphosphonates in which over 60,000 
participants were followed for 3 years or longer. All 4 cur-
rently approved nitrogen-containing bisphosphonates have 
a favorable tolerability and safety profile as indicated by 
the dispensing of over 190 million oral bisphosphonate 
prescriptions worldwide by 2006.59 Their remarkable safety 
profile is partly explained by their strong affinity for bone 
mineral that prevents their uptake by most other tissues, even 
at pharmacologic concentrations. Their retention time in 
the skeleton is long but they are efficiently cleared from the 
systemic circulation, and peak levels are short-lasting. After 
administration, these peak levels are still submicromolar and 
transient, since bisphosphonates are rapidly cleared by skel-
etal uptake and by excretion through the kidneys.7 However, 
trace amounts can be detected in body fluids for very long 
periods after dosing.60,61
After treatment with alendronate (3–10 years), rise-
dronate (3–5 years), or ibandronate (3 years), the incidence 
of overall adverse events, serious adverse events, drug-related 
adverse events, as well as withdrawal rates due to adverse 
events were similar between each treatment and its respective 
placebo arm.15–20,22,52,53 In an open-label follow-up study, the 
safety profile of risedronate was assessed during years 6–7 
of treatment. No additional safety concerns were observed 
when compared with the first 3 or 5 years of treatment.54 In 
an active-control trial, the tolerability profile of IV iban-
dronate over 2 years of treatment was found to be similar 
to that observed with daily oral therapy.38 In the HORIZON 
studies with zoledronate, withdrawal rates due to adverse 
events were similar across treatment and placebo groups.21,41 
However, in the HORIZON Pivotal Fracture Trial, the overall 
incidence of any adverse event was significantly higher in the 
zoledronate group compared with placebo (95.5% vs 93.9%; 
P = 0.002), primarily due to a larger number of events due 
to acute-phase reactions.21
Head-to-head trials
There are very few studies that compare efficacy and safety 
of different bisphosphonates head to head. The FACT trial 
is one example in which the incidence of adverse events, 
serious adverse events, or adverse events leading to discon-
tinuation was found to be similar when groups treated with 
alendronate or risedronate were directly compared. This trial 
included patients affected by upper GI side effects.44 In the 





150 mg monthly were compared. This trial also showed that 
the rates of adverse events, serious adverse events, adverse 
events leading to withdrawal, and upper GI tract adverse 
events, were similar across the alendronate and ibandronate 
treatment groups, but with the incidence of short-term events, 
such as influenza-like illness due to acute-phase reactions, 
being greater in the ibandronate treatment group.46,47
Adverse effects attributed to 
bisphosphonates
Adverse events attributed to bisphosphonates are identi-
fied from various sources which provide different levels of 
confidence that the effects are truly due to the drugs. Thus, 
events identified in RCTs should represent the best evidence 
for an association, since randomization should ensure that 
placebo and treatment groups are matched in other respects 
than the treatment they received. However, even in the case 
of RCTs, the large number of types of adverse events that 
are recorded means that occasionally significant differences 
(,5%) will arise by chance alone. The occurrence of AF 
in the HORIZON trials with zoledronate could represent a 
possible example.
The weakest evidence for an association between a drug 
and an adverse event is derived from postmarketing spon-
taneously reported cases or case series where the incidence 
of such effects in the untreated population is unknown. 
Intermediate levels of association can be derived from many 
other sources, eg, investigator-driven trials, epidemiologic 
studies, and registry data. A further criterion that should be 
applied when assessing whether an adverse event is truly 
related to the drug or whether there is a plausible mechanism 
for the association. Thus, “well recognized” adverse events 
for which there is a plausible mechanistic basis include GI 
intolerance, effects on renal function, and the development of 
acute-phase reactions, particularly after the first IV adminis-
tration. These adverse events can in most cases be avoided or 
managed effectively. A greater challenge, however, is how to 
properly assess adverse events where no clear causal associa-
tion or explanation exists. Among these events are ONJ, AF, 
subtrochanteric or diaphyseal fractures, esophageal cancer, 
and ocular inflammation.
Gastrointestinal safety
GI problems are often considered to be an inevitable con-
sequence associated with the oral use of bisphosphonates, 
which are currently extensively prescribed (alendronate, 
risedronate, and ibandronate) for the prevention and 
  treatment of osteoporosis. However, the results from the 
major   prospective RCTs assessing the reduction of fractures 
are notable in not showing an excess of GI problems. Oral 
bisphosphonates are in general poorly absorbed (,1%) 
from the intestinal tract, which means that potentially large 
amounts of bisphosphonates can come into contact with the 
GI mucosa at all levels of the GI tract. Indeed diarrhea was 
recognized as a side effect of giving large amounts of the 
early bisphosphonates, etidronate and clodronate, and seems 
not to be an issue with the current clinically used bisphos-
phonates, which are given in smaller amounts.
It is generally acknowledged that upper GI symptoms 
are very common in elderly patients whether or not bispho-
sphonates are given. In contrast, the more severe side effects 
associated with esophageal events such as ulceration are rare 
but potentially more serious, and were noted in particular 
after giving oral pamidronate62 or alendronate.63 In terms 
of practical management, the interference of absorption by 
food as well as these esophageal problems are minimized in 
patients taking oral bisphosphonates on an empty stomach, 
first thing in the morning, with sufficient plain water, while 
remaining in an upright position without eating or further 
drinking for at least 30 minutes (60 minutes in the case of 
ibandronate).64–66 Strict adherence to these instructions is 
thought to reduce the incidence of serious esophageal adverse 
events. Optimal formulation also appears to have a role in 
reducing GI events.
In RCTs of bisphosphonates, upper GI complaints have 
been reported at similar frequencies in placebo and active-
treatment groups. However, postmarketing studies have 
indicated that oral bisphosphonates can be associated with 
GI tract intolerance.67 Studies showed that a significant pro-
portion of patients are less compliant with administration 
instructions outside clinical supervision, and so are more 
likely to experience side effects.68
Alendronate
In the vertebral fracture arm of the FIT trial,15 upper GI tract 
adverse events affected 41.3% and 40.0% of patients in the 
alendronate and placebo group, respectively. In the clinical 
fracture arm, these events affected 47.5% of patients in the 
alendronate group vs 47.2% of placebo patients.16 Three 
years into the long-term extension trial of alendronate, 35.7% 
of patients taking placebo reported upper GI tract adverse 
events compared with 29.8% of patients taking alendronate 
(P = 0.041).51 Patients with prior GI problems were excluded 
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To determine whether there was a relationship between the 
dose of alendronate and the incidence of these events, an 
analysis of data from the 2 arms of the FIT study compared 
reports during the first 2 years of the trial (when patients 
received 5 mg alendronate or placebo) with reports during 
years 3 through 4.5 (when patients received 10-mg alen-
dronate or placebo). The proportion of patients affected by 
upper GI events was similar in the alendronate and placebo 
groups during treatment with 5 mg or 10 mg daily dosing. 
The study further demonstrated that alendronate use was 
not associated with a significant increase in upper GI tract 
events among patients at increased risk of those events (age 
75 years or older, with previous upper GI disease, or using 
nonsteroidal anti-inflammatory drugs [NSAIDs]).69
However, rare but serious upper GI events were recog-
nized as a problem soon after alendronate was launched as 
a daily oral medication. In 1996, de Groen et al63 published 
a summary of the postmarketing adverse event reports on 
alendronate received by Merck up to 5 March 1996. There 
were 199 reported cases of upper GI side effects of which 51 
were classified as being serious or severe out of an estimated 
475,000 patients to whom the drug had been prescribed for 
the treatment of osteoporosis or Paget disease, ie, an inci-
dence rate of about 0.01%.63
Risedronate
Upper GI complaints were the most common adverse events 
reported in the VERT multinational 3-year study, affecting 
27% and 26% of patients in the risedronate and placebo 
groups, respectively.19 During the 2-year extension study, 
the incidence of these events was lower at 12.6% in the 
risedronate group and 13.8% in the placebo group.53 The 
incidence of GI adverse events reported during years 6–7 
was even lower at 9.6% in patients continuously treated 
with risedronate for 7 years and 8.6% in patients receiving 
placebo for the first 5 years and risedronate in the last two 
study years.54 To investigate further the upper GI tract safety 
of risedronate (5 mg/day), data from 9 placebo-controlled, 
phase III clinical trials were pooled to increase statistical 
power and allow the detection of differences between treat-
ment and placebo groups.70 This analysis included 10,068 
men and women, representing approximately 10,500 patient-
years of exposure to risedronate. The results confirmed that 
upper GI tract adverse events were similarly distributed across 
the placebo (29.6% of patients) and risedronate (29.8% of 
patients) groups. Concomitant use of aspirin and/or NSAIDs 
did not result in a higher frequency of upper GI tract adverse 
events in the risedronate group compared with the placebo 
group. The use of H2-receptor antagonists and/or proton pump 
inhibitors also did not lead to significant differences in the 
incidence of these events between risedronate and placebo 
groups. Patients with active GI disease receiving risedronate 
did not experience worsening of their underlying condition 
or an increase in frequency of GI side effects.70
ibandronate
The BONE trial showed comparable rates of upper GI 
tract adverse events in ibandronate and placebo groups, 
over 3 years of treatment.22 Subgroup analysis of patients 
with and without a history of GI disorders indicated that iban-
dronate did not increase the overall risk of upper GI adverse 
events compared with placebo in patients with such a history. 
In addition, among those who used aspirin or NSAIDs, the 
incidence of these events was similar in patients treated with 
ibandronate or placebo.22 The DIVA study revealed lower 
incidences of upper GI disorders in patients treated with 
3-mg ibandronate IV 3 monthly than in patients receiving 
oral therapy 2.5 mg.71
Zoledronate
In the HORIZON Pivotal Fracture Trial, nausea (8.5% vs 
5.2%), vomiting (4.6% vs 3.2%), diarrhea (6.0% vs 5.6%), 
upper abdominal pain (4.6% vs 3.1%), and dyspepsia (4.3% 
vs 4.0%) were reported more frequently in patients treated 
with zoledronate than in placebo patients.72 In the HORIZON 
Recurrent Fracture Trial, only diarrhea occurred numerically 
more often in patients treated with zoledronate (5.2%) as 
compared with placebo (4.7%).72
Generic bisphosphonates  
and gastrointestinal safety
We are now in an era in which the patents on bisphosphonates 
are expiring and individual drugs are becoming available 
as generic formulations. For the treatment of osteoporosis, 
generic alendronate tablets are currently available in the 
United States, Canada, and Europe. Studies with preclini-
cal models have suggested that esophageal irritation was 
greater in animals exposed to generic alendronate than in 
those exposed to branded alendronate.73 Differences in the 
disintegration profiles between the branded and the many 
different generic products available may result in GI prob-
lems. In fact, several studies have demonstrated differences 
in the in vitro disintegration properties between generic and 





can lead to reduced efficacy, since bisphosphonates must be 
taken in the fasting state and contact with food or beverages 
markedly reduces bioavailability. Faster disintegration would 
increase the risk of esophagitis due to prolonged contact of 
the esophagus with bisphosphonates.74 Several generic alen-
dronate products have been reported to have very rapid mean 
disintegration times, similar to those of commercially avail-
able orally disintegrating tablets (nonbisphosphonates).75,76 
Although further investigation is needed, one should be aware 
that rapid disintegration may result in drug exposure in the 
mouth and/or esophagus during swallowing with potential 
adverse effects. There are reports77 that describe the clinical 
performance of patients switched to generic alendronate, 
where reductions in efficacy were noted,78 that may be linked 
to lowered overall performance of the generics.
Renal safety
Bisphosphonates are excreted unaltered through the kidneys 
via filtration and possibly by proximal tubular secretion. 
IV administration produces exposure to high initial con-
centrations of bisphosphonates in the kidney and may be 
associated with acute renal injury. This has not been shown 
for oral bisphosphonates when used as labeled, for the treat-
ment of osteoporosis.
The administration of bisphosphonates is contra-indicated 
for use in patients with severe renal impairment (creatinine 
clearance , 30 mL/min) due to “lack of sufficient clinical 
experience” meaning that patients with at least stage 4 renal 
insufficiency were excluded from these studies.64–66,71,72 
Recent publications indicate that the use of oral bispho-
sphonates (alendronate and risedronate) may be safe and 
effective in patients with glomerular filtration rates less than 
30 mL/min.79–81 However, in clinical practice, one should 
still avoid administering bisphosphonates to patients with 
severe renal impairment because of the possible presence of 
adynamic bone disease, where any further reduction of bone 
turnover could be detrimental.
Alendronate
The efficacy and safety profile of alendronate (5 mg and 
10 mg daily) in patients with reduced renal function were 
evaluated in a post hoc analysis of data from the FIT trial.81 
Compared with placebo, alendronate was equally effective 
in decreasing vertebral and nonvertebral fractures in patients 
with and without reduced renal function. No differences were 
observed in the frequency of adverse events in general, or 
renal adverse events in particular, in alendronate-treated 
patients with or without reduced renal function, indicating 
that data from the alendronate trials have not revealed obvi-
ous detrimental effects on renal function.
Risedronate
The efficacy and safety of risedronate in patients with 
renal impairment were evaluated in a 3-year retrospec-
tive study that used data from 9 risedronate trials.79 The 
incidence of vertebral fractures was significantly lower in 
the risedronate-treated patients than in the placebo group, 
for all subgroups of renal impairment (mild, moderate, 
and severe), indicating that patients with renal impairment 
may also benefit from a reduction in fractures. Vertebral 
fracture incidence in patients treated with risedronate was 
similar across renal impairment subgroups, whereas in 
patients receiving placebo the fracture incidence increased 
with the degree of renal impairment. The frequencies of 
adverse events and renal function-related adverse events 
were similar in the placebo and risedronate (5 mg/day) 
groups, regardless of renal function. A more recent ret-
rospective analysis evaluated the influence of the many 
dosing regimens (5 and 15 mg daily, 35 and 50 mg weekly, 
75 mg 2CDM, and 150 mg OaM) of risedronate on the 
renal function of patients with and without baseline renal 
function impairment or renal risk factors.80 The frequency 
distributions of changes in serum creatinine clearance from 
baseline to end point were not different between placebo 
and risedronate groups, nor between different dosing regi-
mens of risedronate for each of the populations examined. 
Patients with baseline renal impairment or baseline renal 
risk factors also did not show treatment-group differences, 
indicating that risedronate had no obvious effect on these 
renal function parameters across a wide range of doses, 
regimens, and patient populations.80
ibandronate
The renal tolerability and safety of IV ibandronate were com-
pared with that of the daily oral regimen in the DIVA trial. 
The incidence of renal adverse events in the 3 mg 3-monthly 
ibandronate group was low and similar to that observed in 
the 2.5 mg daily group. Serum creatinine levels were also 
similar in both treatment groups at each time point and no 
cases of acute renal failure were reported.37
Zoledronate
In the HORIZON trial, the incidence of renal adverse events 
over 3 years was similar in the groups given zoledronate 
or placebo.21,41,72 Small and transient increases in serum 
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9 or 11 days after the infusion, but at 3 years there was no 
systemic deterioration in estimated creatinine clearance. 
However, treatment with zoledronate for conditions other 
than osteoporosis, such as metastatic bone disease and 
hypercalcemia of malignancy, has been associated with 
renal impairment and, in rare cases, acute renal failure.72 
Longer infusion times are known to minimize renal effects 
of IV bisphosphonates. Severe nephrotoxicity can be largely 
avoided by adherence to guidelines for monitoring serum 
creatinine prior to each treatment, temporarily withholding 
therapy in the setting of renal insufficiency, and adjusting 
doses in patients with preexisting chronic kidney disease,82 
and prolonging infusion times.
Symptoms associated  
with an acute-phase reaction
Symptoms consistent with short-term acute-phase reac-
tions, including influenza-like illness and pyrexia, chills, 
myalgia, and arthralgia have been known to be associated 
with the administration of IV bisphosphonates since the 
use of pamidronate and other nitrogen-containing bispho-
sphonates from the 1970s onwards.83,84 The acute-phase 
response is now a well-recognized feature with any of the 
nitrogen-containing bisphosphonates given IV at sufficient 
doses and can also occur after high oral doses. The underly-
ing mechanisms have been studied in detail and appear to 
involve a rapid and profuse production of proinflammatory 
cytokines by peripheral blood gamma delta (γδ) T cells. 
This is mediated by the release of isopentenyl pyrophos-
phate (IPP) as a result of the blockade of the mevalonate 
pathway.85–88 IPP would subsequently activate/expand γδ 
T cells by acting on a receptor that recognizes phosphate 
compounds.
In the case of IV zoledronate in the HORIZON trial, 
the proportion of patients who had any of the 5 most com-
mon acute-phase reaction symptoms (influenza-like illness, 
pyrexia, myalgia, headache, and arthralgia) within 3 days 
after the first infusion was significantly higher in the zole-
dronate group (31.6%) than in the placebo group (6.2%). The 
proportion of patients affected after subsequent infusions 
decreased substantially,21 although in some patients the 
symptoms associated with an acute-phase reaction occurred 
after subsequent doses. In the HORIZON trial to study the 
effect of zoledronate in preventing subsequent fracture after 
a hip fracture, these transient acute-phase reactions occurred 
less commonly, probably due to the routine administration of 
acetaminophen, although there was still a higher incidence 
in the zoledronate group (6.8% vs 0.7%).41
In the case of ibandronate, in the DIVA study, the 
incidence of influenza-like illness, myalgia, and arthralgia, 
reported within 3 days of dosing and with a duration of less 
than 7 days, although generally low, was higher in patients 
receiving IV 3-monthly ibandronate (3.6, 1.3, and 1.3%, 
respectively) than in patients receiving oral formulations 
(0.6, 0.2, and 0.2%, respectively).37 The MOBILE study 
also revealed a higher proportion of patients diagnosed with 
influenza-like illness in the group given 150 mg OaM oral 
ibandronate (3.3%) than the 2.5 mg daily comparator (0.3%). 
These events were of short duration (1–4 days) and were 
associated with the first-administered dose.36
In the case of risedronate, based on reporting any of 
33 acute-phase reaction-like symptoms within 5 days of 
the first dose, active-comparator studies with risedronate 
75 mg 2CDM showed an incidence of acute-phase reactions 
in 7.6% of patients compared with 3.6% in patients receiving 
risedronate 5 mg daily. For the 150 mg OaM oral regimen of 
risedronate, the overall incidence of acute-phase reactions 
(based on reporting any of 33 symptoms within 3 days of the 
first dose) was 5.2% compared with 1.1% in the 5 mg daily 
group.65 These symptoms lasted for up to 7 days.
Bone, joint, or muscle pain
In postmarketing experience, there are infrequent case reports 
describing severe and occasionally incapacitating bone, joint, 
and/or muscle pain in patients taking bisphosphonates. The 
pain could occur days, months, or even years after starting 
bisphosphonates. It is probably different or, at least, not 
only associated with the acute-phase response and presents 
within the first few days after the first treatment with an IV 
bisphosphonate. Most patients reported relief of symptoms 
after discontinuing therapy and a subset had recurrence of 
pain when restarting treatment with the same or a different 
bisphosphonate.64–66,71,72,89 In spite of these case reports, there 
is minimal evidence from RCTs that these symptoms are 
linked to bisphosphonate therapy nor is there any obvious 
underlying mechanism. In placebo-controlled trials of alen-
dronate (FIT), risedronate (VERT), and ibandronate (BONE), 
the incidence of these symptoms was similar in the treatment 
and placebo groups.64–66 However, in the HORIZON trials, 
bone and musculoskeletal pain were reported more frequently 
in the zoledronate group than in the placebo group.21,41,72
Atrial fibrillation
AF came to attention as a possible side effect of bisphospho-
nate therapy in the HORIZON Pivotal Fracture Trial in which 





taking zoledronate than in recipients of placebo. The vast 
majority of AF events were reported more than 30 days after 
infusion, by which time zoledronate would be at extremely 
low concentrations in the circulation. A total of 50 patients 
in the zoledronate group had serious AF (1.3%), compared 
with 20 patients (0.5%) in the placebo group (P , 0.001), 
whereas the incidence of any AF events was similar between 
treatment and placebo groups (2.4% vs 1.9%; P = 0.12).21 In 
the Recurrent Fracture arm of the HORIZON trial, there was 
no evidence of this potential adverse event as the frequency 
of serious AF was similar in the zoledronate and placebo 
groups (1.1% vs 1.3%; P = 0.84), as was the incidence of 
any AF event.41
The linkage of AF to bisphosphonates is even less clear 
with oral therapy.90 Cummings et al91 reported a trend towards 
an increased risk of serious but not all AF events in recipients 
of alendronate compared with placebo in the FIT trial. In 
the alendronate group, 47 patients (1.5%) were reported to 
have serious AF vs 31 patients (1.0%) in the placebo group 
(P = 0.07). Furthermore, an analysis of data from risedronate 
phase III clinical trials involving approximately 15,000 
patients, receiving oral daily doses for up to 3 years, did not 
provide evidence of increased AF in general or serious AF.92 
The incidence of any AF or serious AF events was 1.4% 
and 0.5%, respectively, in the placebo group compared with 
1.4% and 0.6%, respectively, in patients treated with 5-mg 
risedronate (P = 1.0 and P = 0.49). There was also no differ-
ence in the rate of AF in patients treated with 150 mg OaM 
of risedronate (0.6%) vs 5 mg daily (0.5%).31 Recently, an 
analysis of pooled data from 4 pivotal ibandronate clinical 
trials showed no association with increased incidence of 
AF.93
Case–control studies have been undertaken to assess 
the association between AF and bisphosphonate use. One 
of these studies analyzing data from the United States 
reported an increased risk of AF with the use of alendronate,94 
whereas 2 reports from Denmark found no evidence that 
bisphosphonate use could increase such a risk.95,96
No evidence of an overall long-term increased risk of 
AF or flutter associated with continued exposure to alen-
dronate or risedronate was found in a UK study assessing 
the risk of AF and flutter in women on an oral bisphospho-
nate.97 Most recently, a publication of the results from a 
meta-analysis stated that the heterogeneity of the existing 
evidence, as well as paucity of information on some of the 
agents, precludes any definitive conclusion on the exact 
nature of the risk.98
In October 2007, the FDA began reviewing placebo-
controlled clinical trial information of alendronate, rise-
dronate, ibandronate, and zoledronate to explore the potential 
risk of AF in patients treated with these agents. The review 
included data on 19,687 bisphosphonate-treated patients 
and 18,358 placebo-treated patients who were followed for 
6 months to 3 years. In November 2008, the FDA issued 
a statement indicating that their review revealed no clear 
association between overall bisphosphonate exposure and 
the incidence of AF. It was also reported that increasing the 
dose or duration of therapy was not linked to an increased 
risk of AF.99 Similarly, a Europe-wide review, including 
clinical trial data, spontaneous reports of suspected adverse 
drug reactions, and published literature, concluded that the 
risk of AF in association with bisphosphonate treatment 
appears to be low, and the balance of risks and benefits for 
bisphosphonates remains favorable.100 Nevertheless, after 
the European Medicines Agency review, information on the 
incidence of AF was included in the Summary of Product 
Characteristics for zoledronate.101
Ocular inflammation
There have been occasional reports in the medical literature 
over many years indicating that bisphosphonates may be 
associated with ocular inflammation including conjunctivitis, 
iritis, episcleritis, scleritis, and uveitis.102,103 This was first 
recorded in spontaneous case reports with etidronate and 
other bisphosphonates. However, the trials with alendronate 
did not report this type of event64 and in active-control 2-year 
studies of risedronate, none of the patients treated with 75 mg 
2CDM or 150 mg OaM reported ocular inflammation, whereas 
3 patients treated with the active comparator (5-mg risedronate 
daily) developed an inflammatory reaction.65 In the trials 
with ibandronate, there were reports of ocular inflammation 
in patients treated with ibandronate 2.5 mg daily, whereas 2 
patients receiving 150 mg OaM ibandronate experienced ocu-
lar reactions.66 In the HORIZON trials, the number of patients 
developing ocular inflammation was higher in patients treated 
with zoledronate when compared with placebo.21,41 Inflam-
mation appeared within the first 15 days after the infusion. In 
addition, a few recent studies in cancer patients have reported 
ocular inflammation as a complication of zoledronate therapy, 
particularly after the first infusion.104–107 This complication 
can resolve after a short course of corticosteroid treatment. 
Prevention includes the avoidance of bisphosphonates or 
caution in their use (especially IV) for those with a history 
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esophageal cancer
Since the launch of the first oral amino-containing bisphos-
phonate, alendronate, in 1995 and up through May 2008, the 
FDA received reports of 23 cases of patients in the United 
States diagnosed with esophageal cancer, with alendronate 
as the suspect drug in 21 of them and the concomitant 
drug in the other 2 cases and this information was recently 
published.108 In the same publication, the characteristics of 
another group of 31 patients from Europe and Japan who had 
been treated with oral bisphosphonates (the vast majority on 
alendronate) were recorded. Risk factors were not described 
for all patients, but some were taking oral bisphosphonates 
despite absolute contraindications such as Barrett esopha-
gus. Also, for some cases, the time from drug exposure to 
diagnosis was 6 months or less which makes the possibility 
of a causal relationship extremely unlikely. In an attempt 
to determine whether these rates of esophageal cancer are 
any different from the background rates in the population, 
Abrahamsen et al96 used data from the Danish national regis-
try. They individually matched 13,678 patients who suffered 
a fracture and filled more than 1 prescription for any oral bis-
phosphonate with 27,356 patients who suffered a fracture but 
were not treated with a bisphosphonate. The 2 groups were 
similar with respect to age, sex, and fracture type. Interest-
ingly, the risk of esophageal cancer was significantly lower 
in those patients who were taking a bisphosphonate (62% 
on alendronate, 36% on etidronate, and 2% on risedronate, 
ibandronate, or clodronate) when compared with the con-
trols (hazard ratio = 0.35%; 95% confidence interval [CI], 
0.14–0.85; P = 0.02). They also found that the risk of gastric 
cancer was not significantly different between the 2 groups 
(hazard ratio = 1.23%; 95% CI, 0.68–2.22; P = 0.49). The 
reporting of esophageal cancer as a possible complication of 
bisphosphonate therapy illustrates the pitfalls of case reports 
being used to support such claims when the background rates 
of the population are not taken into account. Moreover, there 
is no plausible mechanism by which such cancers are likely 
to be truly associated with bisphosphonate therapy.
In contrast, it has been suggested that bisphosphonates 
may be associated with a reduced rather than increased risk of 
certain cancers, eg, breast cancers.109 Such an association might 
be explained in part by low endogenous estrogen levels being 
associated both with breast cancer and with osteoporosis.
Osteonecrosis of the jaw
Since 2003, there have been a flurry of case reports and 
case series suggesting that bisphosphonate use may be 
associated with a condition called ONJ, which has many 
apparent similarities to osteomyelitis. Despite a substantial 
number of publications on the topic of bisphosphonates and 
ONJ, there are no prospective studies that demonstrate that 
bisphosphonate therapy contributes to the pathogenesis of 
this condition. Since the reported association is based on 
uncontrolled studies and the use of bisphosphonates has 
been used to define the condition (eg, bisphosphonate-related 
ONJ), it has been difficult to separate the background rates 
of ONJ-like pathologies such as osteomyelitis in the popu-
lations under study.110 Even though, in early reports, some 
authors suggested that oral bisphosphonates caused ONJ 
in patients with osteoporosis, more careful analysis of the 
relationship suggests that ONJ occurs only rarely in such 
patients whether treated with bisphosphonates or not. Indeed, 
recent systematic reviews of published and unpublished cases 
indicate that the use of bisphosphonates for osteoporosis is 
associated with an ONJ incidence of less than 1 in 100,000 
patient-years of exposure,111,112 but the background rate of 
occurrence for comparison is unknown. The lack of reliable 
data and consistent definition of disease makes the incidence 
very difficult to determine.110,113
ONJ appears to occur most often in patients with 
advanced cancer, particularly in those with multiple myeloma 
or breast cancer, and specifically in those undergoing dental 
procedures.111,114 Many of these patients receive IV bis-
phosphonates as a necessary part of their treatment, but a 
direct and plausible causal association or pathophysiologic 
mechanism between bisphosphonates and ONJ has not been 
established.
The most reliable method for determining whether 
ONJ is associated with the use of bisphosphonates would 
be through prospective trials in which the incidence of 
ONJ in patients receiving bisphosphonates vs patients not 
receiving bisphosphonates would be compared and where 
all other health parameters are essentially equal. On this 
basis, all trials conducted to date show no evidence of asso-
ciation in osteoporosis or in cancer populations that also 
show no excess of ONJ cases in the bisphosphonate group 
compared with controls. In clinical trials of alendronate, 
risedronate, and ibandronate for osteoporosis indications, 
no cases of ONJ have been reported. In the HORIZON 
Pivotal Fracture Trial (an RCT involving approximately 
8,000 patients), symptoms and signs consistent with ONJ 
developed in only 1 patient treated with zoledronate and 
1 patient in the placebo group. Both cases resolved after 





The pathophysiology of ONJ is unclear and indeed infec-
tion is a common feature, suggesting that many of the lesions 
might be better defined as a form of osteomyelitis.115 The use 
of the term “osteonecrosis” may, therefore, be inappropriate. 
The current definition of ONJ is based on clinical findings and 
includes nonhealing lesions with exposed bone, but without 
requiring formal evidence of bone necrosis.111,116 ONJ has 
been described in patients never exposed to bisphospho-
nates and regions of necrotic bone have been identified as a 
normal finding in the mandible of elderly individuals who 
have never received bisphosphonates.117 Osteonecrosis is a 
well-recognized phenomenon at other skeletal sites such as 
the hip and knee, but there is no evidence that osteonecrosis at 
either of these sites has any association with bisphosphonates. 
Interestingly, in these cases, therapy with bisphosphonates 
has even been reported to have beneficial outcomes in terms 
of preventing the progression of joint damage.118
Despite considerable effort, it has proved very difficult 
to produce lesions that might be relevant to human ONJ 
in animal models. None of the animal models to date fully 
simulate the human condition.119,120 The absence of appropri-
ate animal models121 has also hampered efforts to search for 
plausible mechanisms.
Many pathogenic factors have been postulated to explain 
how bisphosphonates may play a role in ONJ. These include 
effects on blood supply, angiogenesis, excessive bone turn-
over in jaws leading to increased bisphosphonate uptake, 
excessive suppression by bisphosphonates of osteoclastic 
bone resorption,122 impaired mucosal healing,123 and use of 
other drugs (eg, immunosuppresives and glucocorticoids). 
Based on close scrutiny of the current evidence, none provide 
a plausible mechanism for how the use of bisphosphonates 
could lead to ONJ.
The premise that jawbones have an excessively high 
turnover relative to other parts of the skeleton, or that they 
selectively accumulate bisphosphonates, is in contrast to the 
work of Boyde and Kingsmill,117 whose findings suggest 
that turnover in the jawbones of elderly women is actually 
lower than many other skeletal sites, particularly trabecular 
bones. Also, in a study by Bauss et al,124 administration 
of ibandronate to male Wistar rats showed no evidence of 
preferential uptake in the jaw.
The suggestion that markers of bone resorption might be 
used to identify susceptible patients also does not stand up 
to close scrutiny.111,122,125–128
There are now reports from clinical trials of ONJ occur-
ring in patients with advanced cancers in whom denosumab 
has been compared with zoledronate. The numbers of cases 
of ONJ were similar in both groups. There are no reports of 
ONJ when denosumab is given to patients with osteoporosis 
or with nondisseminated cancers, a finding which could be 
interpreted as meaning that ONJ may be associated with the 
advanced cancers per se rather than with the antiresorptive 
drugs.
Health care providers have been encouraged to advise 
their patients to practice good oral hygiene and have regular 
dental visits. If an invasive dental procedure is required, there 
is no evidence that discontinuation of bisphosphonate therapy 
improves dental outcomes,111 although many guidelines 
recommend some form of interruption.129
Subtrochanteric or diaphyseal fractures
A possible association between prolonged alendronate 
therapy and the occurrence of atypical subtrochanteric or 
diaphyseal fractures is a further example of adverse effects 
coming to attention as a result of publication of case reports 
and series. These fractures have been postulated to be the 
result of excessive reduction of bone remodeling.130–133 They 
often have a characteristic radiographic pattern, defined as 
a simple transverse fracture with a unicortical break in an 
area of cortical hypertrophy. Nevertheless, findings from a 
recent registry-based national cohort study from Denmark 
involving nearly 16,000 patients suggest that subtrochanteric 
fractures are likely to occur as a result of osteoporosis, and 
not as a complication of alendronate therapy.134 No reports 
have provided evidence of a possible link between the use of 
risedronate, ibandronate, or zoledronate and the occurrence 
of subtrochanteric fractures. In addition, a review of patients 
(n = 3412) who presented with clinical fractures over a period 
of 3 years revealed that subtrochanteric fractures represent 
less than 1% of all clinical fractures in patients older than 50 
years, and that more than 90% of these fractures occurred in 
patients not taking bisphosphonates at the time of fracture.135 
Mechanisms more plausible than “over-suppression” of bone 
turnover are, therefore, needed to explain the large majority of 
these fractures. Indeed, in a study of a patient on alendronate 
who eventually sustained bilateral fractures at the level of 
the femoral diaphysis, although bone formation was lower 
at the site of the fracture than in the iliac crest, the number of 
osteoclasts in the femoral cortex was 6-fold higher than in the 
iliac cancellous bone.136 Moreover, these osteoclasts had all 
the morphologic characteristics of normal active osteoclasts, 
and no resemblance to the giant osteoclasts described previ-
ously in patients treated with alendronate.137
Following a Europe-wide review of atypical stress frac-
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Products for Human Use (CHMP) introduced a new warning 
including information about these fractures into the Summary 
of Product Characteristics for alendronate.138 The CHMP 
further highlighted the uncertainty of a class effect for the 
other bisphosphonates and that unnecessary and inappropri-
ate switching of bisphosphonates should be avoided. This 
concern has been reflected in the United Kingdom in recent 
safety advice from the Medicines and Healthcare products 
Regulatory Agency.139
effects of bisphosphonates  
on bone turnover
Bisphosphonates exert their therapeutic effects by reduc-
ing bone resorption, and this leads to a reduction in bone 
remodeling and turnover. Since the effects of bisphospho-
nates on these processes can be very substantial, there has 
been a longstanding concern about whether there can be an 
“over-suppression” of bone turnover. The critical question is 
whether turnover can be reduced to an extent that impairs the 
repair of naturally occurring microdamage, thereby reducing 
the strength and mechanical quality of bone.140
Accumulation of bone microdamage has been reported 
in dogs after administration of alendronate at 5 times the 
clinical dose used for treatment of postmenopausal osteopo-
rosis141 and also in skeletally mature female beagles given 
alendronate or risedronate.142 There is some evidence for 
accumulation of microdamage in postmenopausal women 
treated with alendronate,143 but it is uncertain whether this 
leads to any change in mechanical properties. In contrast, 
microcrack frequency was found to be low when investigated 
in transiliac bone biopsies in 50 postmenopausal osteoporotic 
women treated with different nitrogen-containing bisphos-
phonates for at least 3 years.144
The degree of reduction of bone turnover achieved by each 
bisphosphonate, as well as the duration of action appears to 
be associated with their mineral-binding affinity and skeletal 
retention. Bisphosphonates with higher mineral-binding 
affinity and potential retention, such as alendronate and 
zoledronate, are associated with greater reduction of bone 
turnover and have a longer duration of effect after treatment is 
stopped. Bisphosphonates with lower mineral-binding affinity 
and retention, such as risedronate and etidronate, appear to 
reduce bone turnover less and this effect seems to be more 
readily reversible when therapy stops.7 In patients treated for 
5 years with alendronate, bone turnover markers remained 
reduced, well below premenopausal levels for up to 5 years 
after discontinuation of treatment.52 Furthermore, following a 
single infusion of zoledronate, reduced bone turnover (close 
to the maximal achieved suppression) was sustained for at 
least 1 year.21 In patients treated for 3 years or 7 years57 with 
risedronate, bone turnover markers returned to pretreatment 
levels within 1 year after discontinuation of treatment.56
The effect of bisphosphonates on bone has also been 
assessed in several studies through histologic evaluation of bone 
biopsies, to determine both efficacy and safety. Such studies 
uniformly show that bisphosphonates reduce the “activation 
frequency” for the production of new remodeling units in bone. 
In patients treated with alendronate for up to 3 years, bone 
structure was maintained and no signs of impaired mineraliza-
tion were observed.145 Similarly, histologic evaluations of bone 
biopsies from postmenopausal women receiving risedronate for 
up to 3 years showed preserved bone architecture and quality 
without evidence of osteomalacia, impaired bone mineraliza-
tion, or other pathologic findings.18,146 Results from the BONE 
study also indicate that treatment with ibandronate for up to 3 
years does not adversely affect bone quality and architecture, 
with histologic findings showing no signs of impaired miner-
alization, osteomalacia, marrow fibrosis, or cellular toxicity.147 
Patients receiving an annual dosing of zoledronate for 3 years 
had a preserved trabecular bone structure and mineralization 
without evidence of adverse features.148
Finally, it should be noted that treatment with denosumab, 
a fully human monoclonal antibody that inhibits receptor acti-
vator of NF-kappa B ligand action, blocks the differentiation 
of osteoclasts and profoundly reduces bone resorption with-
out, so far, any evidence of this being harmful. Denosumab 
appears to reduce turnover even more than bisphosphonates 
(alendronate was used as the comparator), though the effect 
of dramatic suppression of bone metabolic markers is rapidly 
reversible after only a few months.149 In the phase III clinical 
trials in osteoporosis, denosumab reduced fractures at all sites 
to an extent similar to that achieved with zoledronate.150,151
For how long should bisphosphonates  
be given? The relevance of reversibility  
of effects
Once bisphosphonate therapy is initiated, it is often asked 
whether treatment should be continued indefinitely, 
or whether “drug holidays” should be recommended, 
after 5 years or so. This debate raises the questions of whether 
prolonged reduction of bone turnover is ever harmful, and 
how rapidly the benefits of therapy for reducing fractures are 
lost when treatment stops. There is insufficient information to 
give unequivocal answers to these questions. However, it is 
important to tailor the treatment to the needs of the individual 





the same. As discussed early, when longer-acting bisphos-
phonates such as alendronate and zoledronate are used, the 
effects on reducing bone turnover are likely to persist for 
longer after stopping treatment than with the more reversible 
bisphosphonates such as risedronate and etidronate.
A recent review of the available evidence on long-term 
efficacy and safety of osteoporosis treatments indicated 
that it may be beneficial to continue osteoporosis therapy 
indefinitely in the majority of patients, with discontinua-
tion of treatment likely to do more harm than if treatment 
is continued.152
interactions with PTH and implications 
for sequential therapy
Treatment with parathyroid hormone (PTH) is currently 
the only therapeutic means of stimulating bone formation. 
In practice, many patients will have received bisphospho-
nates before this treatment, which may interfere with a 
subsequent “anabolic” response to PTH. Several studies 
suggest that the early treatment response to teriparatide 
(PTH 1–34) is attenuated by prior or concurrent treatment 
with alendronate.153–157 However, there are some reports 
that previous treatment with alendronate, risedronate, or 
nonbisphosphonate antiresorptive regimens does not affect 
the response to teriparatide.158,159 Nevertheless, bisphos-
phonates with a longer duration of action may interfere 
more with the response to PTH therapy than bisphos-
phonates with a more rapidly reversible effect. This is a 
possible explanation for the findings from a recent study, 
which evaluated the early anabolic effects of teriparatide 
in postmenopausal women with osteoporosis previously 
treated with alendronate or risedronate for at least 2 
years.160 The results indicated that after 3 months of teri-
paratide treatment, patients who had received risedronate 
before had significantly greater increases in markers of 
bone formation than those who had previously received 
alendronate. The greater responsiveness to teriparatide in 
patients who had previously received risedronate rather 
than alendronate was also seen with changes in bone 
mass and some estimates of bone strength.161 This was 
still apparent after 1 year of treatment with teriparatide.160 
It should be noted that regardless of prior treatment, the 
increase in bone formation induced by teriparatide was 
substantial, although the studies were not designed to 
test whether the beneficial effects on fractures was also 
maintained. There is emerging evidence that when PTH 
and zoledronate are given together there is no impairment 
of the response to PTH.
Safety of nondaily oral  
bisphosphonate regimens
A less frequent dosing regimen can offer the patient greater 
convenience in dosing and, therefore, possibly lead to greater 
compliance. There is now a substantial amount of informa-
tion about the safety and efficacy of these alternate dosing 
regimens.
Alendronate
A 2-year active-control study of alendronate demonstrated 
that the tolerability profile and the proportions of patients 
discontinuing therapy due to adverse events were similar 
between daily 10 mg and weekly 70 mg treatment groups. 
Upper GI disorders occurred in 29.3% of patients receiving 
once-weekly alendronate and in 30% of patients receiving 
daily treatment.26 In a 3-month placebo-controlled clinical 
trial, once-weekly alendronate showed a tolerability profile 
comparable with placebo.162 A post hoc subgroup analysis of 
this trial indicated that the concomitant use of NSAIDs does 
not worsen the upper GI tolerability profile of once-weekly 
alendronate compared with placebo.163
Risedronate
In active-control studies, 5 mg daily and 35 mg weekly regi-
mens of risedronate showed comparable safety profiles after 
both 1 and 2 years of treatment.29 In addition, the incidence 
and type of adverse events in general and GI side effects in 
particular were similar to what was reported for the daily 
regimen in placebo-controlled trials.18,19 Monthly regimens 
of risedronate (75 mg 2CDM and 150 mg OaM) also showed 
a tolerability profile similar to that of daily regimen. The 
incidences of adverse events, adverse events leading to 
withdrawal, and upper GI tract adverse events were similar 
in both patient groups.30,31 Among the most common adverse 
events (abdominal pain, diarrhea, constipation, arthralgia, 
and influenza-like illness), only diarrhea and influenza-like 
illness had a substantially higher incidence in the OaM regi-
men compared with daily administration.31
ibandronate
The active-control 2-year study of ibandronate, MOBILE, 
indicated that oral 2.5 mg daily and 150 mg OaM ibandronate 
regimens have similar safety profiles.36 The incidences of 
adverse events, drug-related adverse events, and drug-related 
adverse events leading to discontinuation were well balanced 
across both regimens. The incidence of upper GI tract side 
effects was also similar in both treatment groups. When only 
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were considered, the upper GI tolerability profile of the 2 
dosing regimens continued to be equivalent. Additional 
analyses from the MOTION study showed that GI tolerability 
with once-monthly 150 mg ibandronate therapy was similar 
to that of weekly 70-mg alendronate.47
Conclusion
As a drug class, bisphosphonates share many common prop-
erties; however, each has a unique pharmacologic profile 
that may help to explain potential clinical differences. It is 
well established that bisphosphonates can reduce the risk of 
fracture in men and women with osteoporosis and that they 
are generally viewed as well tolerated and safe, regardless 
of dosing regimen. When considering the various adverse 
events associated with bisphosphonates, it is important in 
each case to consider the strength of the evidence for a causal 
relationship, the benefit – risk profile of the chosen drug and 
the characteristics of the individual patient.
Although the issues of safety are of paramount impor-
tance, it is clear that some adverse events are receiving 
disproportionate attention given the scientifically inadequate 
data (eg, the risk for developing ONJ in patients treated with 
bisphosphonates for osteoporosis). It is important that these 
uncommon events do not deter clinicians from recognizing 
the value that appropriate use of these drugs can achieve in 
reducing fractures in many patients with osteoporosis. This is 
especially relevant when even today the majority of patients 
with fractures related to osteoporosis remain untreated.
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